In the realm of advanced pharmaceuticals, the synergistic combination of active ingredients is often key to overcoming complex health challenges. Cilastatin Sodium, a pharmaceutical intermediate identified by CAS number 1538-09-6, exemplifies this principle through its crucial partnership with the antibiotic Imipenem. For procurement managers and research scientists, understanding the role and sourcing of high-quality Cilastatin Sodium is fundamental to producing effective treatments for severe bacterial infections.

Imipenem is a broad-spectrum carbapenem antibiotic known for its potent bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. However, its utility is limited by its rapid metabolism by the enzyme dehydropeptidase I in the renal tubules. Cilastatin Sodium is specifically formulated to counteract this limitation. By inhibiting dehydropeptidase I, Cilastatin Sodium safeguards Imipenem from premature breakdown, thereby increasing its concentration in the bloodstream and urinary tract, and significantly broadening its spectrum of antibacterial action. This synergistic effect makes the combination indispensable for treating serious infections that do not respond to other antibiotics.

For pharmaceutical companies aiming to buy Cilastatin Sodium, specifying high purity, typically exceeding 99%, is essential. This level of purity ensures that the final drug product meets stringent pharmacopoeial standards and regulatory requirements, guaranteeing safety and efficacy for patients. Equally critical is the sourcing of GMP (Good Manufacturing Practice) certified material. GMP compliance signifies that the intermediate is manufactured under strict quality control measures, from raw material handling to final packaging, assuring consistency and reliability in every batch.

As a major global hub for pharmaceutical raw materials, China offers numerous opportunities for sourcing Cilastatin Sodium. Buyers should focus on identifying manufacturers with a proven track record in producing high-quality pharmaceutical intermediates. Establishing a relationship with a trusted supplier involves evaluating their production capacity, adherence to quality standards, and responsiveness to inquiries regarding pricing and delivery timelines. Obtaining detailed quotes and technical specifications is a critical step in the procurement process.

In conclusion, the effective treatment of severe bacterial infections often relies on the synergistic action of drugs like Imipenem, made possible by intermediates such as Cilastatin Sodium (1538-09-6). By prioritizing high-purity, GMP-certified materials and partnering with reputable suppliers, pharmaceutical manufacturers can ensure the consistent quality and efficacy of their antibiotic formulations. If your organization is looking to purchase Cilastatin Sodium, engaging with leading global suppliers will provide access to this vital intermediate and support your critical manufacturing needs.